India’s obesity treatment market is set to expand rapidly as local drugmakers prepare to release affordable versions of Novo Nordisk’s drug following patent expiration. The anticipated price drop could drive demand, prompting clinics and hospitals to enhance obesity services to meet the rising need.
Generic medicine makers prepare to launch affordable options after Novo’s patent for Ozempic, Wegovy expires
